Ondine Biomedical

Mölnlycke Deal And US Trials Will Open International Markets

AnalystConsensusTarget

Not Invested

Consensus Narrative from Analysts

Published

18 May 25

Updated

11 Jun 25

AnalystConsensusTarget's Fair Value

UK£0.55

75.5% undervalued

11 Jun

UK£0.14

78.8%

3.8%

Author's Valuation

UK£0.6

75.5% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

UK£0.6

75.5% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

0.00%

Medical Equipment revenue growth rate

0.31%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.74%

Calculation

CA$5.82m

Earnings '28

188.34x

PE Ratio '28

CA$1.10b

Market Cap '28

CA$1.10b

Market Cap '28

887.60m

No. shares '28

CA$1.24

Share Price '28

CA$1.24 Share Price '28

Discounted to 2025 @ 6.69% p.a.

CA$1.02

Fair Value '25

CA$1.02 Fair Value '25

Converted to GBP @ 0.5405 CAD/GBP Exchange Rate

UK£0.55

Fair Value '25